Lundbeck preps for war against generic drugmakers in US

Lundbeck is facing a patent dispute concerning its second-best selling drug, schizophrenia treatment Rexulti, against companies wanting to reproduce generic versions. CEO Deborah Dunsire will sound the charge this summer.

Photo: Lundbeck / PR

Pharmaceutical firm Lundbeck is arming itself for battle with several generic drugmakers wanting to produce generic versions of schizophrenia treatment Rexulti before its patent expires.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs